P1172: DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA FROM THE PHASE 2 PRIMO TRIAL: UPDATED EXPANSION PHASE ANALYSIS

• P. L. Zinzani, MD, PhD,
• J. Zain, MD,
• M. Mead, BS, MD,
• C. Casulo, MD,
• E. D. Jacobsen, MD,
• G. Gritti, MD, PhD,
• L. Pinter-Brown, MD,
• K. Isutzu, MD,
• D. Cohan, MD,
• M. Daugherty, PharmD,
• J. E. Brammer, MD,
• N. Mehta-Shah, MD,
• B. Pro, MD,
• S. M. Horwitz, MD

Affiliations

P. L. Zinzani, MD, PhD

J. Zain, MD

1 Institute of Hematology “Seràgnoli”, University of Bologna, Bologna, Italy

M. Mead, BS, MD

C. Casulo, MD

3 Department of Medicine, Division of Hematology/Oncology, UCLA Medical Center, Santa Monica

E. D. Jacobsen, MD

4 University of Rochester Medical Center, James P. Wilmot Cancer Center, Rochester

G. Gritti, MD, PhD

5 Dana-Farber Cancer Institute, Boston, United States of America

L. Pinter-Brown, MD

6 Hematology and Bone Marrow Transplant Unit, Ospedale Papa Giovanni XXIII, Bergamo, Italy

K. Isutzu, MD

7 University of California-Irvine, Irvine, United States of America

D. Cohan, MD

8 National Cancer Center Hospital, Tokyo, Japan

M. Daugherty, PharmD

9 Secura Bio, Inc.

J. E. Brammer, MD

10 SecuraBio, Inc, Las Vegas

N. Mehta-Shah, MD

11 Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus

B. Pro, MD

12 Washington University School of Medicine in St. Louis, Saint Louis

S. M. Horwitz, MD

13 Columbia University Herbert Irving Comprehensive Cancer Center